About Vaxxinity
Vaxxinity is a company based in Dallas (United States) founded in 2019.. Vaxxinity has raised $26.96 million across 1 funding round. Vaxxinity operates in a competitive market with competitors including Brii Biosciences, Affinivax, Osivax, Diamyd Medical and Pardes Biosciences, among others.
- Headquarter Dallas, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Vaxxinity, Inc.
-
Annual Revenue
$00as on Dec 31, 2023
-
Net Profit
$-56.93 M24.31as on Dec 31, 2023
-
EBITDA
$-56.05 M24.56as on Dec 31, 2023
-
Total Equity Funding
$26.96 M (USD)
in 1 rounds
-
Latest Funding Round
$26.96 M (USD), Series B
Mar 31, 2021
-
Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Vaxxinity
Vaxxinity is a publicly listed company on the OTC with ticker symbol VAXX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Funding Insights of Vaxxinity
Vaxxinity has successfully raised a total of $26.96M through 1 strategic funding round. The most recent funding activity was a Series B round of $26.96 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series B — $27.0M
-
First Round
First Round
(31 Mar 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Series B - Vaxxinity | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Vaxxinity
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Vaxxinity
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Vaxxinity Comparisons
Competitors of Vaxxinity
Vaxxinity operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, Affinivax, Osivax, Diamyd Medical and Pardes Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
|
| domain | founded_year | HQ Location |
Technology-based conjugate vaccines against infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines against mutating pathogens are developed using nanoparticle technology.
|
|
| domain | founded_year | HQ Location |
Therapies for autoimmune diabetes treatment and prevention are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for pandemic diseases including SARS-CoV-2 are developed.
|
|
| domain | founded_year | HQ Location |
Developing and licensing novel drugs for diseases including cancer and autoimmune diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Vaxxinity
Frequently Asked Questions about Vaxxinity
When was Vaxxinity founded?
Vaxxinity was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Vaxxinity located?
Vaxxinity is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Is Vaxxinity a funded company?
Vaxxinity is a funded company, having raised a total of $26.96M across 1 funding round to date. The company's 1st funding round was a Series B of $26.96M, raised on Mar 31, 2021.
What does Vaxxinity do?
Vaxxinity was established in 2019 in Dallas, United States, within the biotechnology sector. Focus is placed on developing vaccines addressing neurological disorders and infectious diseases through proprietary synthetic peptide immunogens. These immunogens activate B- and T-cell responses while combining multiple antigens into multitope formulations. Key candidates include UB-612 for COVID-19, UB-311 and Tau for Alzheimers disease, UB-312 for Parkinsons disease, UB-313 for chronic migraine, and PCSK9 for hypercholesterolemia.
Who are the top competitors of Vaxxinity?
Vaxxinity's top competitors include Brii Biosciences, Osivax and CStone Pharma.
Is Vaxxinity publicly traded?
Yes, Vaxxinity is publicly traded on OTC under the ticker symbol VAXX.
What is Vaxxinity's ticker symbol?
The ticker symbol of Vaxxinity is VAXX on OTC.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.